HSBC Analysts Give MorphoSys (ETR:MOR) a €81.00 Price Target

HSBC set a €81.00 ($94.19) target price on MorphoSys (ETR:MOR) in a report issued on Friday morning, Borsen Zeitung reports. The brokerage currently has a sell rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Deutsche Bank set a €133.00 ($154.65) target price on shares of MorphoSys and gave the company a buy rating in a report on Thursday, August 8th. Independent Research set a €116.00 ($134.88) target price on shares of MorphoSys and gave the company a neutral rating in a report on Tuesday, August 13th. Royal Bank of Canada set a €130.00 ($151.16) target price on shares of MorphoSys and gave the company a buy rating in a report on Friday, August 9th. JPMorgan Chase & Co. set a €120.00 ($139.53) target price on shares of MorphoSys and gave the company a buy rating in a report on Wednesday, August 7th. Finally, Berenberg Bank set a €150.00 ($174.42) target price on shares of MorphoSys and gave the company a buy rating in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of €118.56 ($137.86).

Shares of ETR:MOR opened at €111.50 ($129.65) on Friday. The company has a debt-to-equity ratio of 8.61, a current ratio of 7.62 and a quick ratio of 7.40. The company’s 50-day moving average price is €101.31 and its two-hundred day moving average price is €92.15. The stock has a market capitalization of $3.52 billion and a PE ratio of -84.41. MorphoSys has a one year low of €76.45 ($88.90) and a one year high of €114.60 ($133.26).

About MorphoSys

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Further Reading: What are the economic characteristics of a bear market?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.